



# IJPPR

INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH  
An official Publication of Human Journals

ISSN 2349-7203



Human Journals

**Review Article**

May 2020 Vol.:18, Issue:2

© All rights are reserved by Swati Patil et al.

## Panchagavya: An Unexplored Pathy in Healthcare



**IJPPR**  
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH  
An official Publication of Human Journals



ISSN 2349-7203

**Swati Patil<sup>1\*</sup>, Hanmanthrao Palep<sup>2</sup>, Snehal Funde<sup>1</sup>**

*1 Principal K. M. Kundnani College of Pharmacy,  
Mumbai, India.*

*2 Dr. Palep's Medical Research Foundation, Mumbai,  
India.*

**Submission:** 23 April 2020  
**Accepted:** 01 May 2020  
**Published:** 30 May 2020

**Keywords:** Ayurveda, Panchagavya, Healthcare

### ABSTRACT

Faecal transplant was first documented in 4<sup>th</sup> century China, known as “yellow soup”. Faecal microbiota transplantation (FMT) refers to the infusion of a faecal suspension from a healthy person into the gastrointestinal (GI) tract of another person to cure a specific disease. But instead of administrating human feces why not try out traditional Ayurveda, since thousands of years, we worship cow as “KAMADEHNU”, the God who fulfills our desire, give robust health and eliminates diseases, that is, Cow faecal transplantation in the form of PANCHAGAVYA, since it fits into our culture and also well accepted culturally and claimed to be prime rich resource base which has been clearly said in ancient text "*Gomaye Vasate Laxmi*". Panchagavya is a system of medicine just like homeopathy, allopathy, or naturopathy. We aim to decode the message and basis of this practice in modern scientific language.




HUMAN JOURNALS

[www.ijppr.humanjournals.com](http://www.ijppr.humanjournals.com)

## INTRODUCTION

Panchagavya involves the use of five by-products of cow viz. Cow dung, urine, milk, curd, and ghee. The Ayurveda, the ancient Indian system of medicine, has detailed mentions of the importance of cow's milk, curd, ghee, urine in the treatment of various human ailments. The ancient ayurvedic literature (Charak Samhita, Sushrut, Gadanigrah) suggests several pharmacological Applications of the substances obtained from Panchgavya. Religious ritual of Practice of Panchagavya prashan has been in existence for ages in our country. This practice was expected to deliver a person from all the sins. Sin in Sanskrit means papma. Papma is a synonym for disease. This ritual is practiced once every year during July and August at which time the *Vaccinia viraemia* is at its peak in cows. A systematic work needs to be carried out on chemical nature, biological activity, microbiology, and pharmaceutical aspects and mechanism of bioactive compounds in Panchgavya. In the recent past due emphasis has not been given to cow therapy by the scientific community. We aim to decode the message and basis of this practice in modern scientific language.

**Human gut microbiome:** Human being is considered as Meta organism due to a symbiotic relationship with gut microflora. The human body has 100 trillions of microbes almost ten times more than body cells. It is like a forgotten organ. Aggregate genes in the microbiome are almost hundred times that of the human genome. Gut brain axis is now a fact. It consists of 3000-10000 species. Most of it makes up in colon is almost 60% dry mass of feces. Thus relation is not just simply a commensal, but a rather mutualistic symbiotic relationship.



**Figure No. 1: Distribution of the normal human gut flora.**

(World J Gastroenterol. 2015 Aug 7; 21(29): 8787–8803)

The normal gut microbiota imparts specific function in host nutrient metabolism, xenobiotic and drug metabolism, maintenance of structural integrity of the gut mucosal barrier, immunomodulation, and protection against pathogens. Several factors play a role in shaping the normal gut microbiota. They include (1) the mode of delivery (vaginal or caesarean); (2) diet during infancy (breast milk or formula feeds) and adulthood (vegan-based or meat-based); and (3) use of antibiotics or antibiotic like molecules that are derived from the environment of the gut commensal community. A major concern of antibiotic use is the long-term alteration of the normal healthy gut microbiota and horizontal transfer of resistance genes that could result in a reservoir of organisms with a multidrug-resistant gene pool.

A preliminary study was carried out to confer the microbiological growth in every sample of panchagavya and a few combinations too.

Excellent microbial growth was observed in single samples of panchagavya. Good microbial growth was observed in the sample incubated with cow ghee compared to the sample incubated without ghee.

**Table No. 1: Microbial count by the plating method**

| Sr. No. | Samples   | CUF/ml               |
|---------|---|----------------------|
| 1       | Cow dung  | $4.8 \times 10^7$    |
| 2       | Cow urine   | $3.2 \times 10^7$    |
| 3       | Cow milk  | $5.6 \times 10^8$    |
| 4       | Cow curd  | $6.1 \times 10^8$    |
| 5       | Cow ghee  | $2.9 \times 10^8$    |
| 6       | Cow dung + Cow urine                                  | $3.6 \times 10^8$    |
| 7       | Cow milk + Cow curd                                   | $3.9 \times 10^9$    |
| 8       | Cow dung + Cow urine + Cow milk + Cow curd            | $4.2 \times 10^9$    |
| 9       | Cow dung + Cow urine + Cow milk + Cow curd + Cow ghee | $3.8 \times 10^{10}$ |

### Properties of Panchagavya:

Panchagavya is by no means a new therapeutic modality, although it was only relatively recently that stool was shown to be a biologically active, complex mixture of living organisms with great therapeutic potential for recurrent *Clostridium difficile* infection and perhaps other GI and non-GI disorders.

Lyophilized Panchagavya helps in the optimized delivery of microbes as it provides enteric coating because of ghee. It enables to control of acid levels in the stomach.

Probiotic: The World Health Organization defines probiotics as live microorganisms that can provide benefits to human health when administered in adequate amounts. Several species such as *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus bulgaricus*, *Lactobacillus acidophilus*, *Bifidobacterium longum*, *Bifidobacterium infantis*, *Streptococcus thermophilus*, *E. coli* strain, to name a few have been shown to impart immunomodulatory and gut barrier functions. These and several others have been used commercially in the management of human illnesses e.g., IBD and antibiotic-associated diarrhea. The fundamental concept of using these organisms in the treatment armamentarium is mimicking the physiological health-promoting functions of the “good” bacteria. The addition of a prebiotic could augment the effect of the probiotics. Prebiotics are defined as food ingredients that contain non-digestible oligosaccharides (e.g., galactooligosaccharides and inulin); and a probiotic and prebiotic are together called a synbiotic. The gut bacteria selectively ferment these fibers resulting in the synthesis of SCFAs, which in turn imparts the pro-health effects. Thus panchagavya acts as a health promoter.

### Indications for Panchagavya:


1. Inflammatory bowel disease: Some suspect that IBD is due to a reduction in immune tolerance and subsequent overreaction of the host's immune system to harmful or non-harmful bacteria. IBD may be caused by the entire gut flora together or some specific types.

Some also suspect that inflammation in IBD is due to increased permeability of the inner lining of the colon, which may allow bacteria to invade the tissues and cause an immune reaction that leads to prolonged inflammation. Tissue damage in IBD results from the immunological misperception of danger within the naturally occurring flora or due to failure of normal tolerance to pathogenic bacteria. It is still unclear whether the inflammation that occurs is due to a specific subset of intestinal microbes or due to a problem with the tolerance of commensal gut flora.

2. Obesity: It is a physiological state that has emerged as a major health concern in populations. From literature, the animal models of obesity, the interplay between the dominant gut phyla, Bacteroidetes and Firmicutes, are shifted with a significant reduction of the former and a corresponding increase in the latter. The shift in the relative abundances of these phyla results in an increased capacity for harvesting energy from food and produces low-level inflammation. Several changes in host genetics and environmental factors have been used to induce obesity in animal models and thus provoke a change in microbiota composition. Remarkably, the energy harvest phenotype is transmissible simply by transplanting the obese microbiota.

3. Crohn's disease: It is a chronic gastrointestinal disorder with an unknown etiology characterized by an inflammatory response of the intestinal mucosa. An influential study by Cadwell et al. Sheds light on how the virome, genome, and microbiota might be interacting in the development of Crohn's disease. The gut microbiota, in addition to the virome and host genetics, were shown to play an important role in the etiology of a complex mammalian disease.

4. Autoimmune diseases: The auto-immune diseases (Diabetes, Multiple sclerosis, Psoriasis, etc) all result from inappropriate action of the adaptive immune system mediated by the gut microbiota. The introduction of bacterial polysaccharides from the commensal *Bacteroides fragilis* protects against the development of these autoimmune diseases.



**Figure No. 2: Effect of Interactions of Bacteria, Viruses, and Eukaryotes in Health and Disease**

(World J Gastroenterol. 2015 Aug 7; 21(29): 8787–8803)

Diseases have been traditionally studied under a paradigm of “one microbe, one disease.” However, a new understanding is emerging on how disease phenotypes are a result of complex interactions between bacteria, viruses, and eukaryotes, as well as their interactions with the host or with certain drugs. Virulence of some eukaryotes is, for instance, linked to the presence of certain bacteria, such as in the case of *E. histolytica* and *E. coli* or *S. dysenteriae*. The susceptibility of the host to viral infections is conditioned by the particular configuration of the microbiota, whereas herpesvirus infection can confer resistance to certain bacterial infections. Antibiotics can significantly reshape the composition of the microbiota. As a clear correlation has been observed between many diseases and dysbiosis, the widespread use of antibiotics may be linked to the dramatic increase observed in autoimmune diseases over the last years. Conversely, helminths confer resistance to autoimmune diseases.

As we have seen, disease states are often correlated with imbalances in the gut microbiota. Restoring a healthy microbial community by the administration of panchagavya can be

proven to be a valuable tool in the treatment of certain diseases and also allow the impact of the microbiota in determining phenotype to be tested. For instance, obesity and several disease phenotypes induced by changes in host genetics cause dysbiosis in the gut. Remarkably, these phenotypes can be transferred to germ-free wild-type hosts simply by inoculating them with the microbiota from the deceased donors. Furthermore, the administration of panchagavya to a diseased individual can help in recovering microbial balance in the gut.

## CONCLUSION

Taken together, the findings we have reviewed that to further advance our understanding of health and disease, we will require an improved characterization of the variability in the microbiota, a better understanding of how such variability can result in similar or different functional profiles, and more integrative studies that take into account the interaction between the microbiota, the host, and the environment to produce a phenotype. An increasing variety of disease states and disorders are being found to correlate with the host microbiota. Furthermore, detailed studies are to be done to elucidate microorganisms that show similarity to any identified culturable/non-culturable microbes.

## REFERENCES

1. Dr. H.S. Palep.,2004, *Scientific Foundation Of Ayurveda*, Chaukhamba Sanskrit Pratishthan, Delhi,170-172.
2. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, Zhang M, Oh PL, Nehrenberg D, Hua K, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. *Proc. Natl. Acad. Sci. USA.* 2010;107:18933–18938.
3. Blaser M. Antibiotic overuse: Stop the killing of beneficial bacteria. *Nature.* 2011;476:393– 394.
4. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature.*2008;456:259–263.
5. Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. *Cell.*2010;141:1135–1145.
6. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. *Gut.* 2009;58:1091–1103.
7. Knights D, Costello EK, Knight R. Supervised classification of human microbiota. *FEMS Microbiol. Rev.*2011;35:343–359.
8. Peterson DA, McNulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. *Cell Host Microbe.*2007;2:328–339
9. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley RE. Succession of microbial consortia in the developing infant gut microbiome. *Proc. Natl. Acad. Sci. USA.* 2011;108(Suppl 1):4578–4585. Published online July 28, 2010. 10.1073/pnas.1000081110.
10. Fulzele SV, Satturwar PM, Joshi SB, and Dorle AK. 2003. Study of the immunomodulatory activity

Haridradi ghrita in rats. *Indian Journal of Pharmacology*, 35:51-54.

11. Mackie, W. and L. McCartney, *Practical medical Microbiology*. Edn 13. Churchill Living stone, London,1989.
12. Srivastava R, Aragno M & Sharma A K, Cow dung extract: A medium for the growth of pseudomonads enhancing their efficiency as biofertilizer and biocontrol agent in rice, *Indian J Microbiol*, 50 (2010)349-354.
13. Adegunloye D V, Adetuyi F C, Akinyosoye F A & Doyeni M O, Microbial analysis of compost using cow dung as booster, *Pak J Nutr*, 6 (2007)506-510.
14. Sathasivam A, Muthuselvam M & Rajendran R, Antimicrobial activities of cow urine distillate against some clinical pathogens, *Global J Pharmacol*, 4 (2010)41-44.
15. Basak A B & Lee M W, In vitro inhibitory activity of cow urine and cow dung of *Fusarium solani* f. sp. *cucurbitae*, *Mycobiology*, 30 (2002)51-54.
16. Mary CA, Dev VPS, Karunakaran K & Nair NR, Cow dung extract for controlling bacterial blight, *Int Rice Res News*, 11 (1986)19.
17. Ozutsumi Y, Hayashi H, Sakamoto M, Itabashi H & Benno Y, Culture-independent analysis of fecal microbiota in cattle, *Biosci Biotechnol Biochem*, 69 (2005)1793-1797.
18. Nocker A, Burr M & Camper A K, Genotypic microbial community profiling: A critical technical review, *Microb Ecol*, 54 (2007)276-289.
19. Zeyaulah M, Kamli M R, Islam B, Atif M, Benkhayal F A, et al, Metagenomics—An advanced approach for noncultivable micro-organisms, *Biotechnol Mol Biol Rev*, 4 (2009) 49-54.
20. Earald E, Edwin S, Tiwari V, Garg R, Toppo E. Antioxidant and antimicrobial activities of cow urine. *Glob J Pharmacol*.2008;2:20–2.
21. Badadani M, SureshBabu SV, Shetty KT. Optimum conditions of autoclaving for hydrolysis of proteins and urinary peptides of prolyl and hydroxypropyl residues and HPLC analysis. *J Chromatogr B Analyt Technol Biomed Life Sci*.2007;847:267–74.
22. Upadhyay RK, Dwivedi P, Ahmad S. Antimicrobial activity of photo-activated cow urine against certain pathogenic bacterial strains. *Afr J Biotechnol*.2010;9:518–22.
23. Hu W, Murphy MR, Constable PD, Block E. Dietary cation-anion difference effects on performance and acid-base status of dairy cows postpartum. *J Dairy Sci*.2007;90:3367–75.
24. Naotoshi K, Osamu Y, Yoshihiko S, Fuminobu M, Masahiro Y, Yoshimitsu M. Clinicopathological findings in peripartum dairy cows fed anion salts lowering the dietary cation-anion difference: Involvement of serum inorganic phosphorus, chloride and plasma estrogen concentrations in milk fever. *Jpn J Vet Res*.2007;55:3–12.
25. Turi M, Turi E, Koljalg S, Mikelsaar M. Influence of aqueous extracts of medicinal plants on surface hydrophobicity of *Escherichia coli* strains of different origin. *APMIS*. 1997;105:956– 62.
26. Chauhan RS, Singhal L. Harmful effects of Pesticides and their control through cowpathy. *Int J Cow Sci*.2006;2:61–70.
27. P.J. Turnbaugh, R.E. Ley, M. Hamady, C. Fraser-Liggett, R. Knight, The human microbiome project, *Nature*, 449 (7164) (2007), pp.804-810.
28. Xu, J.I. Gordon, Honor thy symbionts, *Proc Natl Acad Sci U S A*, 100 (18) (2003), pp. 10452-10459.
29. Sun S, Lourie R, Cohen SB, et al. Epithelial Sell1L is required for the maintenance of intestinal homeostasis. *Mol Biol Cell*2016;27:483–490.
30. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci U S A*2011;108(Suppl 1):4659–4665.
31. Crost EH, Tailford LE, LeGallG, et al. Utilisation of mucin glycans by the human gut symbiont *Ruminococcus gnavus* is strain-dependent. *PLoS One*2013;8:e76341.
32. C.-H. Tseng, C.-Y. Wu, The gut microbiome in obesity, *J Formos Med Assoc*, 118 (2019), pp. S3-S9.
33. Holmes E, Loo RL, Stampler J, Bictash M, Yap IKS, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. *Nature* 2008;439-549.
34. Routy B, Gopalakrishnan V, Daillere R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. *Nat Rev Clin Oncol* 2018;153-8296.